Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Did You Know Previous | All Articles This Week | Next
This article originally posted and appeared in  MedicationSGLT2Issue 731

Empagliflozin (an SGLT2 inhibitor) Approved by European Commission

The European Commission has approved empagliflozin 10 mg and 25 mg once-daily tablets for use in adults when glycemic control is not achieved from diet and exercise. The European Commission endorsed empagliflozin for approval in March after the U.S. FDA delayed the approval and requested more data. A new drug application has been accepted by the FDA for a combination of empagliflozin and linagliptin, though, and will be reviewed. This approval is based on more than 10 international trials looking at more than 13,000 adults with type 2 diabetes. The phase 3 studies produced significantly reduced HbA1c, body weight and blood pressure when used as monotherapy and in combination with preexisting treatments. Lilly News Release, Mau 2014 

Advertisement
Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 29 May, 2014 and appeared in  MedicationSGLT2Issue 731

Past five issues: SGLT-2 Inhibitors Special Edition October 2014 | Diabetes Clinical Mastery Series Issue 211 | Issue 751 | Humulin Insulin Special Edition October 2014 | Diabetes Clinical Mastery Series Issue 210 |

2014 Most Popular Articles:

FDA Approves Once-Weekly GLP-1 Diabetes Treatment Regimen for T2DM
Posted September 25, 2014
Stanley Schwartz, MD: A New Way of Classifying Diabetes - The Beta-Cell Centric Approach
Posted September 29, 2014
Two Positive Phase 3 Trials for ITCA 650 (Exenatide, a GLP-1 Agonist) in Type 2 Diabetes
Posted October 10, 2014
EASD: Insulin Pumps Lower Mortality Rate 29% Compared to Multiple Injections in T1DM
Posted October 03, 2014
Best Insulin Regimen for Type 1's
Posted October 10, 2014
GLP-1 Agonist Medications Chart
Posted September 23, 2014
Non-Caloric Artificial Sweeteners May Induce Glucose Intolerance
Posted October 10, 2014
Handbook of Diabetes, 4th Ed., Excerpt #13: Control and Complications
Posted October 13, 2014
FDA Approves an Eye Drug for Diabetic Patients
Posted September 25, 2014
New GLP-1 Receptor Agonist as an Alternative to Insulin Glargine?
Posted October 10, 2014


Browse by Feature Writer & Article Category.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Maria Emanuel Ryan, DDS, PhD | Marilyn Porter, RD, CDE | Melissa Diane Smith | Michael R. Cohen, RPh, MS, ScD, FASHP | Paul Chous, M.A., OD | Philip A. Wood PhD | R. Keith Campbell, Professor, B.Pharm, MBA, CDE | Richard K. Bernstein, MD | Sheri R. Colberg PhD | Sherri Shafer | Stanley Schwartz, MD, FACP, FACE | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |

Cast Your Vote
Do your teenage patients manage their diabetes well?
CME/CE of the Week
Vickie Driver, DPM, MS, FACFAS

Category: Wound Care
Credits: 1.0



Search Articles On Diabetes In Control